Chawla R K, Shlaer S M, Lawson D H, Murray T G, Schmidt F, Shoji M, Nixon D W, Richmond A, Rudman D
Cancer Res. 1980 Nov;40(11):3915-20.
The plasma and 24-hr urinary levels of cyclic adenosine 3':5'-monophosphate and of cyclic guanosine 3':5'-monophosphate (cGMP) were determined for 19 healthy normal patients, 54 patients with six types of nonneoplastic diseases (cholelithiasis, peptic ulcer, coronary heart disease, hypertension, regional ileitis, and cirrhosis), and 54 patients with five types of neoplastic disease (cancers of the lung, colon, and breast, acute myelocyte leukemia, and Hodgkin's disease). The cyclic adenosine 3':5'-monophosphate levels of urine and plasma in normal subjects, in noncancer subjects, and in cancer subjects did not differ significantly. The cGMP levels in the noncancer group were similarly unchanged from those in the normal group. However, mean cGMP levels in the urine and plasma of patients with neoplastic diseases were, respectively, 2- and 3-fold greater than the normal values (p less than 0.005 for urine and p less than 0.05 for plasma). Pharmacokinetic studies with [3H]cGMP in nine healthy controls and 15 patients with neoplasia showed that the mean production rate of this nucleotide in patients with metastatic cancer was elevated when compared to normal patients, but many values fell within the normal range. In acute leukemia, the production rate was seven times normal, with four of five patients having values clearly outside the normal range. The plasma clearance rate in patients with neoplasia was not decreased when compared to that in normal patients. It is proposed that an increased production rate, rather than any change in plasma clearance, accounts for the increased levels of cGMP in the plasma and urine of some patients with neoplastic disease.
对19名健康正常受试者、54名患有六种非肿瘤性疾病（胆石症、消化性溃疡、冠心病、高血压、局限性回肠炎和肝硬化）的患者以及54名患有五种肿瘤性疾病（肺癌、结肠癌和乳腺癌、急性髓细胞白血病和霍奇金病）的患者，测定了血浆和24小时尿中环磷酸腺苷（cAMP）及环磷酸鸟苷（cGMP）的水平。正常受试者、非癌症受试者和癌症受试者尿液及血浆中的cAMP水平无显著差异。非癌症组的cGMP水平与正常组同样无变化。然而，肿瘤性疾病患者尿液和血浆中的平均cGMP水平分别比正常值高2倍和3倍（尿液p<0.005，血浆p<0.05）。对9名健康对照者和15名肿瘤患者进行的[3H]cGMP药代动力学研究表明，与正常患者相比，转移性癌症患者中这种核苷酸的平均生成率升高，但许多值仍在正常范围内。在急性白血病中，生成率是正常的7倍，5名患者中有4名的值明显超出正常范围。与正常患者相比，肿瘤患者的血浆清除率并未降低。有人提出，生成率增加而非血浆清除率的任何变化，是导致一些肿瘤性疾病患者血浆和尿液中cGMP水平升高的原因。
